|
US2020103416A1
|
|
SNX9 as a novel biomarker for chronic inflammation and associated immunosuppresion and a new regulator of T cell receptor expression and function
|
|
CN111052232A
|
|
Method and system for enhancing speech signals of human speakers in video using visual information
|
|
US2020163695A1
|
|
Device, system and method for pericardial access
|
|
CN107847484A
|
|
For treating the nitroxid of breathing problem
|
|
IL227541D0
|
|
Antioxidant, anti-inflammatory, anti-radiation, metal chelating compounds and uses thereof
|
|
AU2011213739A1
|
|
Use of lipid conjugates in the treatment of disease
|
|
AU2011205019A1
|
|
Methods and compositions for the inhibition of modulation of T cell costimulatory pathway by a pathogenic agent
|
|
BR112012023979A2
|
|
photochemical electrode, construction and uses thereof.
|
|
MX364303B
|
|
Irrigation control system.
|
|
BRPI0808293A2
|
|
"compositions for nasal administration"
|
|
EP2061583A2
|
|
Organic nanoparticles obtained from microemulsions by solvent evaporation
|
|
AU2007200901A1
|
|
Use of derivatives of valproic acid and 2-valproenic acid amides for the treatment of mania in bipolar disorder
|
|
AU2006253733A1
|
|
Backbone cyclized melanocortin stimulating hormone (alpha S ) analogs
|
|
AU2006213436A1
|
|
Depolymerized polysaccharide-based hydrogel adhesive and methods of use thereof
|
|
AU2005256098A1
|
|
Gastroretentive controlled release pharmaceutical dosage forms
|
|
AU2005303389A1
|
|
Combination therapy associating preferably a ceramide with a cytotoxic drug
|
|
AU2003271042A1
|
|
In Vitro Micro-Organs and Uses Related Thereto
|
|
AU2003272065A1
|
|
Broad-spectrum in-vivo effective superantigen toxin antagonists based on the interaction between cd28 and the superantigen and uses thereof
|
|
AU2003233172A1
|
|
Methods compositions and articles of manufacture for modulating bone growth
|
|
AU2003209577A1
|
|
Amino acid sequences capable of facilitating penetration across a biological barrier
|
